Zacks Investment Research upgraded shares of Albireo Pharma (NASDAQ:ALBO) from a hold rating to a buy rating in a research note published on Tuesday, Zacks.com reports. They currently have $25.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “

A number of other analysts have also recently commented on the stock. William Blair reissued a buy rating on shares of Albireo Pharma in a research note on Monday, July 15th. Cowen reissued a buy rating on shares of Albireo Pharma in a research note on Wednesday, April 17th. Wedbush reissued an outperform rating and set a $69.00 target price on shares of Albireo Pharma in a research note on Friday, August 9th. HC Wainwright reissued a buy rating and set a $62.00 target price on shares of Albireo Pharma in a research note on Sunday, August 11th. Finally, ValuEngine raised shares of Albireo Pharma from a buy rating to a strong-buy rating in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $51.50.

ALBO opened at $23.43 on Tuesday. Albireo Pharma has a fifty-two week low of $19.10 and a fifty-two week high of $38.69. The company has a fifty day moving average of $27.79 and a two-hundred day moving average of $30.48.

Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.09. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%. The company had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $1.11 million. As a group, equities analysts anticipate that Albireo Pharma will post -5.91 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its holdings in shares of Albireo Pharma by 7.2% in the fourth quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock valued at $921,000 after purchasing an additional 2,529 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Albireo Pharma by 40.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock valued at $2,850,000 after purchasing an additional 33,390 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Albireo Pharma by 11.3% in the fourth quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock valued at $2,390,000 after purchasing an additional 9,922 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Albireo Pharma by 87.6% in the fourth quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 3,020 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in shares of Albireo Pharma by 356.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,599 shares in the last quarter. 70.59% of the stock is owned by institutional investors and hedge funds.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.